MX9706647A - Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina. - Google Patents

Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.

Info

Publication number
MX9706647A
MX9706647A MX9706647A MX9706647A MX9706647A MX 9706647 A MX9706647 A MX 9706647A MX 9706647 A MX9706647 A MX 9706647A MX 9706647 A MX9706647 A MX 9706647A MX 9706647 A MX9706647 A MX 9706647A
Authority
MX
Mexico
Prior art keywords
monoamine oxidase
inhibitors
pharmaceutical compositions
composition
treatment
Prior art date
Application number
MX9706647A
Other languages
English (en)
Inventor
Francesca Mary Brewer
Edward Stewart Johnson
Anthony Clarke
Original Assignee
Scherer Ltd R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9706647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9504235.4A external-priority patent/GB9504235D0/en
Application filed by Scherer Ltd R P filed Critical Scherer Ltd R P
Publication of MX9706647A publication Critical patent/MX9706647A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Esta invencion se refiere a una composicion farmacéutica para administracion oral que comprende un portador y como un ingrediente activo, un inhibidor de la oxidasa B de monoamina, caracterizado en que la composicion se formulo para estimular la absorcion pregástrica del inhibidor de la oxidasa (B de monoamina. Un proceso para preparar tal composicion y el uso de tal composicion para el tratamiento del mal de Parkinson, el tratamiento y/o profilaxis de depresion y el tratamiento y/o profilaxis del mal de Alzheimer también se proporcionaron.
MX9706647A 1995-03-02 1997-09-02 Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina. MX9706647A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9504235.4A GB9504235D0 (en) 1995-03-02 1995-03-02 Pharmaceutical compositon
GBGB9517063.5A GB9517063D0 (en) 1995-03-02 1995-08-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX9706647A true MX9706647A (es) 1998-06-30

Family

ID=26306612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706647A MX9706647A (es) 1995-03-02 1997-09-02 Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.

Country Status (26)

Country Link
US (3) US20010021722A1 (es)
EP (1) EP0814789B2 (es)
JP (1) JP3273141B2 (es)
CN (1) CN1171586C (es)
AT (1) ATE241346T1 (es)
AU (1) AU702161B2 (es)
BG (1) BG63862B1 (es)
BR (1) BR9607057A (es)
CA (1) CA2214026C (es)
CZ (1) CZ297382B6 (es)
DE (1) DE69628415T3 (es)
DK (1) DK0814789T4 (es)
EE (1) EE04039B1 (es)
ES (1) ES2199283T5 (es)
GE (1) GEP20012374B (es)
HU (1) HU228852B1 (es)
IS (1) IS2789B (es)
MX (1) MX9706647A (es)
NO (1) NO316804B1 (es)
NZ (2) NZ302723A (es)
PL (1) PL183266B1 (es)
PT (1) PT814789E (es)
SI (1) SI0814789T2 (es)
SK (1) SK284383B6 (es)
TR (1) TR199700878T1 (es)
WO (1) WO1996026720A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
JPH10513455A (ja) 1995-02-10 1998-12-22 ザ ユニバーシティ オブ トロント イノベーションズ ファウンデーション 緑内障治療用のデプレニル化合物
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
GB9717770D0 (en) * 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
GB9802088D0 (en) * 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
CN1251695C (zh) * 1999-04-21 2006-04-19 株式会社柳柳 用于治疗痴呆的含有司来吉兰和银杏提取物的药物组合物
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
RU2389482C2 (ru) * 2004-11-24 2010-05-20 Тева Фармасьютикал Индастриз, Лтд. Композиции разагилина, распадающиеся в ротовой полости
EP1906952A4 (en) * 2005-07-01 2010-04-14 Jenrin Discovery MAO-B INHIBITORS USEFUL IN THE TREATMENT OF OBESITY
CN1911211B (zh) * 2006-08-25 2010-04-14 重庆医药工业研究院有限责任公司 雷沙吉兰口服固体制剂
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20070190187A1 (en) * 2006-09-07 2007-08-16 Kneller Bruce W Formulation for enhanced delivery of phenethylamine
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
AU2010262738A1 (en) * 2009-05-20 2011-10-13 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
CN109152841A (zh) 2016-03-26 2019-01-04 雷迪博士实验室有限公司 N-炔丙胺衍生物的药物组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4454158A (en) * 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
IE53696B1 (en) * 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
JP2660419B2 (ja) * 1988-04-02 1997-10-08 旭電化工業株式会社 安定化された合成樹脂組成物
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192550A (en) † 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
GB9017610D0 (en) * 1990-08-10 1990-09-26 Erba Carlo Spa Antiparkinson mao reversible inhibitor
DE69227467T2 (de) † 1991-12-24 1999-04-22 Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo Intrabukkal desintegrierende zubereitung und ihre herstellung
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU4534593A (en) † 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与

Also Published As

Publication number Publication date
BR9607057A (pt) 1998-06-09
NO316804B1 (no) 2004-05-18
ATE241346T1 (de) 2003-06-15
EP0814789B2 (en) 2008-01-09
PT814789E (pt) 2003-09-30
US20080187573A1 (en) 2008-08-07
CN1178461A (zh) 1998-04-08
JP3273141B2 (ja) 2002-04-08
WO1996026720A1 (en) 1996-09-06
EE9700187A (et) 1998-02-16
PL322046A1 (en) 1998-01-05
IS4553A (is) 1997-08-27
NO974010D0 (no) 1997-09-01
DK0814789T3 (da) 2003-09-01
AU4884696A (en) 1996-09-18
EP0814789B1 (en) 2003-05-28
DE69628415D1 (de) 2003-07-03
SK115897A3 (en) 1998-03-04
US20040091525A1 (en) 2004-05-13
PL183266B1 (pl) 2002-06-28
ES2199283T5 (es) 2008-05-16
AU702161B2 (en) 1999-02-18
DE69628415T2 (de) 2004-03-11
NZ329471A (en) 1999-10-28
EE04039B1 (et) 2003-06-16
US20010021722A1 (en) 2001-09-13
CZ270597A3 (cs) 1998-01-14
HUP9801227A3 (en) 2000-02-28
BG63862B1 (bg) 2003-04-30
SK284383B6 (sk) 2005-02-04
HU228852B1 (en) 2013-06-28
CA2214026C (en) 2007-10-16
HUP9801227A2 (hu) 1999-06-28
EP0814789A1 (en) 1998-01-07
JPH10506409A (ja) 1998-06-23
DE69628415T3 (de) 2008-06-26
NZ302723A (en) 1998-04-27
NO974010L (no) 1997-10-30
ES2199283T3 (es) 2004-02-16
BG101937A (en) 1998-07-31
CZ297382B6 (cs) 2006-11-15
CA2214026A1 (en) 1996-09-06
CN1171586C (zh) 2004-10-20
SI0814789T2 (sl) 2008-04-30
IS2789B (is) 2012-06-15
DK0814789T4 (da) 2008-05-19
GEP20012374B (en) 2001-03-25
SI0814789T1 (en) 2003-12-31
TR199700878T1 (xx) 1998-01-21

Similar Documents

Publication Publication Date Title
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
ATE167057T1 (de) Sublinguales oder bukkales arzneimittel
MY127718A (en) Dolastatin 10 derivatives.
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
FI961809A (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
MX9801305A (es) Composicion de disolucion rapida oral para agonistas de dopamina.
GB9424766D0 (en) Pharmaceutical composition
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AU1185801A (en) Novel compounds
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
IL110011A0 (en) Pharmaceutical compositions for the treatment of schizophrenia
GB2291349B (en) Gemfibrozil containing pharmaceutical compositions
HUP0101326A2 (hu) Paroxetinkompozíciók és eljárás az előállításukra
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1